Document is current
Any future updates will be listed below
-
Authors
Lui, Justin K. https://orcid.org/0000-0002-4745-3766
Gillmeyer, Kari R. https://orcid.org/0000-0002-5333-259X
Sangani, Ruchika A. https://orcid.org/0000-0003-1982-4408
Smyth, Robert J. https://orcid.org/0000-0001-7613-9306
Gopal, Deepa M. https://orcid.org/0000-0003-3534-9360
Trojanowski, Marcin A. https://orcid.org/0000-0003-2583-1591
Bujor, Andreea M. https://orcid.org/0000-0002-8840-8937
Soylemez Wiener, Renda https://orcid.org/0000-0001-7712-2135
LaValley, Michael P. https://orcid.org/0000-0002-8488-5170
Klings, Elizabeth S. https://orcid.org/0000-0003-4879-720X
-
Funding
Funding for this research was provided by:
United Therapeutics Corporation
National Scleroderma Foundation
American Heart Association (23CDA1052352)
Parker B. Francis Fellowship
National Center for Advancing Translational Sciences (1UL1TR001430, 1UL1TR001430)
Doris Duke Charitable Foundation (2021261)
John Templeton Foundation (62288)
National Heart, Lung, and Blood Institute (1R01HL155955-01A1, 1UG3 HL143192-01A1)
VA Boston Healthcare System
National Institute of Arthritis and Musculoskeletal and Skin Diseases (CCCR P30 AR072571)
Health Resources and Services Administration (U1EMC27864‐08‐00)
Bayer
Novo Nordisk
Novartis
- License Information
-
More Information
Article History
Received: 8 July 2023
Accepted: 20 September 2023
First Online: 13 November 2023
Declarations
:
: J.K.L. receives research support from United Therapeutics. E.S.K. received research support from Bayer, Novartis, FORMA Therapeutics/Novo Nordisk, and United Therapeutics. She received royalties for 3 topic cards in UpToDate. She was a consultant/advisory board member for FORMA Therapeutics/Novo Nordisk, Vertex, Omeros Corporation, and CSL Behring for sickle cell disease related clinical trials (no conflict with the present work).
